Abstract Number: 1387 • ACR Convergence 2021
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…Abstract Number: 1635 • ACR Convergence 2021
Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?
Background/Purpose: Nailfold capillary microscopy (NCM) is a cornerstone in the diagnosis of Systemic Sclerosis (SSc) in adulthood. Although Raynaud’s phenomenon (RP) is common in childhood,…Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…Abstract Number: 1396 • ACR Convergence 2020
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…Abstract Number: 149 • 2019 ACR/ARP Annual Meeting
Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon
Background/Purpose: Systemic autoimmune diseases are mostly taught through theoretical lectures, which do not allow for the acquisition of physical examination skills and semiologic confrontation. We…Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…Abstract Number: 1730 • 2018 ACR/ARHP Annual Meeting
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Background/Purpose: Small vessel arteriopathy precedes the development of organ damage and tissue fibrosis in systemic sclerosis (SSc) and related disorders. It is currently considered that…Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…Abstract Number: 2692 • 2018 ACR/ARHP Annual Meeting
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
Background/Purpose: Structural and functional vascular abnormalities occur in Systemic Sclerosis (SSc). We report on the use of High Frequency Ultrasound (HFUS) with Superb Microvascular Imaging…Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…Abstract Number: 745 • 2017 ACR/ARHP Annual Meeting
An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
Background/Purpose: Raynaud’s phenomenon (RP) is consistently ranked highest in patient surveys exploring the frequency and impact of disease related manifestations of systemic sclerosis (SSc). SSc-RP…Abstract Number: 1686 • 2017 ACR/ARHP Annual Meeting
Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge
Background/Purpose: A topical therapy for either prevention or palliation of attacks would offer unique advantages to selected patients with Raynaud phenomenon (RP). This study used…Abstract Number: 1700 • 2017 ACR/ARHP Annual Meeting
Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »